Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
BioPharma Dive
The partners said the shot produced clinically meaningful efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.
pharminent
March 23, 2026 (Last updated: March 24, 2026)
BioPharma Dive
The partners said the shot produced clinically meaningful efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.